Biocon's Q3 profits rise by 65% to Rs 171 cr

The company's businesses in Japan, emerging markets have been witnessing high growth

Biocon, India’s largest biopharma firm, has said that its profits have jumped by 65 per cent to Rs  171 crore in the quarter ended December, and its revenues have increased by 32 per cent to Rs 1,092 crore.

The Bengaluru-based firm saw its operating margins, calculated as sales minus expenditure, at 30 per cent, owing to the significant increase in licensing revenue.

Last year, the company had reported profits worth Rs 104 crore while drawing a revenue of Rs 829 crore in the same period.

“Our strong performance in Q3FY17 was led by robust growth of our Biologics business with